172 related articles for article (PubMed ID: 34333666)
1. The BET bromodomain inhibitor ZEN-3365 targets the Hedgehog signaling pathway in acute myeloid leukemia.
Wellbrock J; Behrmann L; Muschhammer J; Modemann F; Khoury K; Brauneck F; Bokemeyer C; Campeau E; Fiedler W
Ann Hematol; 2021 Dec; 100(12):2933-2941. PubMed ID: 34333666
[TBL] [Abstract][Full Text] [Related]
2. 3-Hydroxyisoindolin-1-one derivates: Synthesis by palladium-catalyzed CH activation as BRD4 inhibitors against human acute myeloid leukemia (AML) cells.
Chen P; Yang Y; Yang L; Tian J; Zhang F; Zhou J; Zhang H
Bioorg Chem; 2019 May; 86():119-125. PubMed ID: 30690335
[TBL] [Abstract][Full Text] [Related]
3. Expression of Hedgehog Pathway Mediator GLI Represents a Negative Prognostic Marker in Human Acute Myeloid Leukemia and Its Inhibition Exerts Antileukemic Effects.
Wellbrock J; Latuske E; Köhler J; Wagner K; Stamm H; Vettorazzi E; Vohwinkel G; Klokow M; Uibeleisen R; Ehm P; Riecken K; Loges S; Thol F; Schubert C; Amling M; Jücker M; Bokemeyer C; Heuser M; Krauter J; Fiedler W
Clin Cancer Res; 2015 May; 21(10):2388-98. PubMed ID: 25745035
[TBL] [Abstract][Full Text] [Related]
4. NANOG Expression as a Responsive Biomarker during Treatment with Hedgehog Signal Inhibitor in Acute Myeloid Leukemia.
Kakiuchi S; Minami Y; Miyata Y; Mizutani Y; Goto H; Kawamoto S; Yakushijin K; Kurata K; Matsuoka H; Minami H
Int J Mol Sci; 2017 Feb; 18(3):. PubMed ID: 28245563
[TBL] [Abstract][Full Text] [Related]
5. Targeting Hedgehog (Hh) Pathway for the Acute Myeloid Leukemia Treatment.
Terao T; Minami Y
Cells; 2019 Apr; 8(4):. PubMed ID: 30987263
[TBL] [Abstract][Full Text] [Related]
6. The BET bromodomain inhibitor I-BET151 acts downstream of smoothened protein to abrogate the growth of hedgehog protein-driven cancers.
Long J; Li B; Rodriguez-Blanco J; Pastori C; Volmar CH; Wahlestedt C; Capobianco A; Bai F; Pei XH; Ayad NG; Robbins DJ
J Biol Chem; 2014 Dec; 289(51):35494-502. PubMed ID: 25355313
[TBL] [Abstract][Full Text] [Related]
7. Acute myeloid leukemia - strategies and challenges for targeting oncogenic Hedgehog/GLI signaling.
Aberger F; Hutterer E; Sternberg C; Del Burgo PJ; Hartmann TN
Cell Commun Signal; 2017 Jan; 15(1):8. PubMed ID: 28122581
[TBL] [Abstract][Full Text] [Related]
8. Hedgehog pathway inhibition as a therapeutic target in acute myeloid leukemia.
Shallis RM; Bewersdorf JP; Boddu PC; Zeidan AM
Expert Rev Anticancer Ther; 2019 Aug; 19(8):717-729. PubMed ID: 31422721
[No Abstract] [Full Text] [Related]
9. Hedgehog Pathway Inhibitors: A New Therapeutic Class for the Treatment of Acute Myeloid Leukemia.
Jamieson C; Martinelli G; Papayannidis C; Cortes JE
Blood Cancer Discov; 2020 Sep; 1(2):134-145. PubMed ID: 34661144
[TBL] [Abstract][Full Text] [Related]
10. Combined inhibition of GLI and FLT3 signaling leads to effective anti-leukemic effects in human acute myeloid leukemia.
Latuske EM; Stamm H; Klokow M; Vohwinkel G; Muschhammer J; Bokemeyer C; Jücker M; Kebenko M; Fiedler W; Wellbrock J
Oncotarget; 2017 Apr; 8(17):29187-29201. PubMed ID: 28418873
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and biological activity evaluation of a series of novel sulfonamide derivatives as BRD4 inhibitors against acute myeloid leukemia.
Feng Z; Chen A; Shi J; Zhou D; Shi W; Qiu Q; Liu X; Huang W; Li J; Qian H; Zhang W
Bioorg Chem; 2021 Jun; 111():104849. PubMed ID: 33798846
[TBL] [Abstract][Full Text] [Related]
12. Hedgehog/GLI signaling in tumor immunity - new therapeutic opportunities and clinical implications.
Grund-Gröschke S; Stockmaier G; Aberger F
Cell Commun Signal; 2019 Dec; 17(1):172. PubMed ID: 31878932
[TBL] [Abstract][Full Text] [Related]
13. Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells.
Fiskus W; Sharma S; Qi J; Valenta JA; Schaub LJ; Shah B; Peth K; Portier BP; Rodriguez M; Devaraj SG; Zhan M; Sheng J; Iyer SP; Bradner JE; Bhalla KN
Mol Cancer Ther; 2014 May; 13(5):1142-54. PubMed ID: 24435446
[TBL] [Abstract][Full Text] [Related]
14. Mechanistic basis and efficacy of targeting the β-catenin-TCF7L2-JMJD6-c-Myc axis to overcome resistance to BET inhibitors.
Saenz DT; Fiskus W; Mill CP; Perera D; Manshouri T; Lara BH; Karkhanis V; Sharma S; Horrigan SK; Bose P; Kadia TM; Masarova L; DiNardo CD; Borthakur G; Khoury JD; Takahashi K; Bhaskara S; Lin CY; Green MR; Coarfa C; Crews CM; Verstovsek S; Bhalla KN
Blood; 2020 Apr; 135(15):1255-1269. PubMed ID: 32068780
[TBL] [Abstract][Full Text] [Related]
15. Targeting Hippo coactivator YAP1 through BET bromodomain inhibition in esophageal adenocarcinoma.
Song S; Li Y; Xu Y; Ma L; Pool Pizzi M; Jin J; Scott AW; Huo L; Wang Y; Lee JH; Bhutani MS; Weston B; Shanbhag ND; Johnson RL; Ajani JA
Mol Oncol; 2020 Jun; 14(6):1410-1426. PubMed ID: 32175692
[TBL] [Abstract][Full Text] [Related]
16. Protein targeting chimeric molecules specific for dual bromodomain 4 (BRD4) and Polo-like kinase 1 (PLK1) proteins in acute myeloid leukemia cells.
Mu X; Bai L; Xu Y; Wang J; Lu H
Biochem Biophys Res Commun; 2020 Jan; 521(4):833-839. PubMed ID: 31708096
[TBL] [Abstract][Full Text] [Related]
17. Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia.
Chapuis N; Tamburini J; Green AS; Vignon C; Bardet V; Neyret A; Pannetier M; Willems L; Park S; Macone A; Maira SM; Ifrah N; Dreyfus F; Herault O; Lacombe C; Mayeux P; Bouscary D
Clin Cancer Res; 2010 Nov; 16(22):5424-35. PubMed ID: 20884625
[TBL] [Abstract][Full Text] [Related]
18. Mebendazole Mediates Proteasomal Degradation of GLI Transcription Factors in Acute Myeloid Leukemia.
Freisleben F; Modemann F; Muschhammer J; Stamm H; Brauneck F; Krispien A; Bokemeyer C; Kirschner KN; Wellbrock J; Fiedler W
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639011
[TBL] [Abstract][Full Text] [Related]
19. BRD4 associates with p53 in DNMT3A-mutated leukemia cells and is implicated in apoptosis by the bromodomain inhibitor JQ1.
Stewart HJ; Horne GA; Bastow S; Chevassut TJ
Cancer Med; 2013 Dec; 2(6):826-35. PubMed ID: 24403256
[TBL] [Abstract][Full Text] [Related]
20. BRD4 bimodal binding at promoters and drug-induced displacement at Pol II pause sites associates with I-BET sensitivity.
Khoueiry P; Ward Gahlawat A; Petretich M; Michon AM; Simola D; Lam E; Furlong EE; Benes V; Dawson MA; Prinjha RK; Drewes G; Grandi P
Epigenetics Chromatin; 2019 Jul; 12(1):39. PubMed ID: 31266503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]